Consistent with the mutation spectrum of patients with CHD being enriched with in-frame NF1 intragenic mutations, these patients had more than two-fold higher risk than patients with truncating mutations to develop CHD (CHD prevalence: in-frame mutations: 22/111 (19.8%) vs. truncating mutations: 37/368 (10.1%), odds ratio = 1.9713, 95% CI: 1.1162–3.4814, p = 0.0193) (Figure 1b). This evidence concerns the gene NF1 and coronary artery disorder.